Strong saline - the effect of repeating doses
- Conditions
- Elevated eyepressureMedDRA version: 16.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersMedDRA version: 16.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- EUCTR2013-001733-41-FI
- Lead Sponsor
- Harju Mika
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 26
Open angle glaucoma and ocular hypertension patients with intraocular pressure 22-34 mmHg
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 13
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 13
Ödemin medication, age under 25 years, age higher than 80 years, kidney failure, heart failure, dementia, other medical disorder that affects significantly patients condition
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Change in eyepressure in two different groups: total dose 1 mmol/kg and two doses of 0.5 mmol/kg between 10 minutes;Secondary Objective: Blood pressure, pulse;Primary end point(s): Eyepressure aften one 1 mmol/kg 23,4% NaCl or after two repeating doses of 0.5 mmol/kg 23,4% NaCl;Timepoint(s) of evaluation of this end point: 20 minutes in 1.0 mmol/kg group and 30 minutes in 0.5 mmol/kg x2 group
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Eyepressure aften one 1 mmol/kg 23,4% NaCl or after two repeating doses of 0.5 mmol/kg 23,4% NaCl;Timepoint(s) of evaluation of this end point: 1.0 mmol/kg group: 0, 3, 6, 13, 10, 13 and 16 minutes. <br>0.5 mmol/kg x2 group: 0, 3, 6, 10, 13, 16, 20, 23 and 26 minutes.